New RAD202 data confirms positive tumor uptake

New RAD202 data confirms positive tumor uptake

Radiopharm Theranostics (RAD:AU) has announced New RAD202 data confirms positive tumor uptake

Download the PDF here.

The Conversation (0)
Appendix 4E and Preliminary Final Report

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
RAD receives IND approval from US FDA for Betabart (RV-01)

RAD receives IND approval from US FDA for Betabart (RV-01)

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+ for Prostate Cancer

Bria-PROS+ is BriaCell's next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manufacturing clinical supplies of Bria-PROS+ and plans to initiate a Phase 1/2a clinical study in... Keep Reading...
BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell"... Keep Reading...
Glowing DNA strand against blue background with digital graphs and glowing bars.

Hantavirus Outbreak Sparks Rollercoaster Ride for Biotech Stocks

A localized hantavirus outbreak aboard an Atlantic cruise ship triggered a brief, speculative frenzy in biotechnology stocks this week.Shares of prominent vaccine developers fluctuated on Monday (May 11) as retail investors attempted to front run what they perceived as a burgeoning global health... Keep Reading...
BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients

BriaCell Phase 3 Bria-IMT Study Enrollment Surpasses 230 Patients

Over 315 patients screened and over 230 patients enrolled in BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong clinical site and patient interestInterim topline data expected in... Keep Reading...

Interactive Chart

Latest Press Releases

Related News